Ioannis Mastoris

Ioannis Mastoris

Auto-generated profile, based on publicly available information

Ioannis Mastoris

Department of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
SRSagar Ranka
Sagar Ranka
IMIoannis Mastoris
Ioannis Mastoris
NKNavin K. Kapur
Navin K. Kapur
RTRyan J. Tedford
Ryan J. Tedford
ARAniket Rali
Aniket Rali
ZSZubair Shah
Zubair Shah
Background: The usefulness of right heart catherization (RHC) has long been debated, and thus, we aimed to study the real‐world impact of the use of RHC in cardiogenic shock. Methods and Results: In the Nationwide Readmissions Database using International Classification of Diseases, Tenth Revision ( ICD‐1 0 ), we identified 236 156 patient hospitalizations with cardiogenic shock between 2016 and 2017. We sought to evaluate the impact of RHC during index hospitalization on management strategies, complications, and outcomes as well as on 30‐day readmission rate. A total 25 840 patients (9.6%) received RHC on index admission. The RHC group had significantly more comorbidities compared with the non‐RHC group. During the index admission, the RHC group had lower death (25.8% versus 39.5%, P <0.001) and stroke rates (3.1% versus 3.4%, P <0.001). Thirty‐day readmission rates (18.7% versus 19.7%, P =0.04) and death on readmission (7.9% versus 9.3%, P =0.03) were also lower in the RHC group. After adjustment, RHC was associated with lower index admission mortality (odds ratio, 0.69; 95% CI, 0.66–0.72), lower stroke rate (odds ratio, 0.81; 95% CI, 0.72–0.90), lower 30‐day readmission (odds ratio, 0.83; 95% CI, 0.78–0.88), and higher left ventricular assist device implantations/orthotopic heart transplants (odds ratio, 6.05; 95% CI, 4.43–8.28) during rehospitalization. Results were not meaningfully different after excluding patients with cardiac arrest. Conclusions: RHC use in cardiogenic shock is associated with improved outcomes and increased use of downstream advanced heart failure therapies. Further blinded randomized studies are required to confirm our findings.

1 January 2022 in Circulation: Heart Failure
Verified
Journal Article
Open access
PDF file
IMIoannis Mastoris
Ioannis Mastoris
JTJoseph Tonna
Joseph Tonna
JHJinxiang Hu
Jinxiang Hu
ASAndrew J. Sauer
Andrew J. Sauer
NHNicholas A. Haglund
Nicholas A. Haglund
ZSZubair Shah
Zubair Shah
Background: There has been increasing use of extracorporeal membrane oxygenation (ECMO) as bridge to heart transplant (orthotopic heart transplant [OHT]) or left ventricular assist device (LVAD) over the last decade. We aimed to provide insights on the population, outcomes, and predictors for the selection of each therapy. Methods: Using the Extracorporeal Life Support Organization Registry between 2010 and 2019, we compared in-hospital mortality and length of stay, predictors of OHT versus LVAD, and predictors of in-hospital mortality for patients with cardiogenic shock that were bridged with ECMO to OHT or LVAD. One hundred sixty-seven patients underwent LVAD versus 234 patients who underwent OHT. Results: The overall use of ECMO has increased from 1.7% in 2010 to 22.2% in 2019. Mortality was similar between groups (LVAD: 28.7% versus OHT: 29.1%) while length of stay was longer for OHT (LVAD: 49.6 versus OHT: 59.5 days, P =0.05). Factors associated with OHT included prior transplant (odds ratio [OR]=31.26 [CI, 3.84–780.5]), use of a temporary pacemaker (OR=6.5 [CI, 1.39–50.15]), and increased use of inotropes on ECMO (OR=3.77 [CI, 1.39–11.07]), whereas LVAD use was associated with weight (OR=0.98 [CI, 0.97–0.99]), cardiogenic shock presentation (OR=0.40 [CI, 0.21–0.78]), previous LVAD (OR=0.01 [CI, 0.0001–0.22]), respiratory failure (OR=0.28 [CI, 0.11–0.70]), and milrinone infusion (OR=0.32 [CI, 0.15–0.67]). Older age (OR=1.07 [CI, 1.02–1.12]), cannulation bleeding (OR=26.1 [CI, 4.32–221.3]), and surgical bleeding (OR=6.7 [CI, 1.26–39.9]) in patients receiving LVAD and respiratory failure (OR=5 [CI, 1.17–23.1]) and continuous renal replacement therapy (OR=3.82 [CI, 1.28–11.9]) in patients receiving OHT were associated with increased mortality. Conclusions: ECMO use as a bridge to advanced therapies has increased over time, with more patients undergoing LVAD than OHT. Mortality was equal between the 2 groups while length of stay was longer for OHT.

1 February 2023 in Cardiac Failure Review
Verified
Journal Article
Open access
PDF file
IMIoannis Mastoris
Ioannis Mastoris
EDErsilia M DeFilippis
Ersilia M DeFilippis
TMTrejeeve Martyn
Trejeeve Martyn
AMAlanna A Morris
Alanna A Morris
HSHarriette Gc Van Spall
Harriette Gc Van Spall
ASAndrew J Sauer
Andrew J Sauer
Remote patient monitoring (RPM), within the larger context of telehealth expansion, has been established as an effective and safe means of care for patients with heart failure (HF) during the recent pandemic. Of the demographic groups, female patients and black patients are under-enrolled relative to disease distribution in clinical trials and are under-referred for RPM, including remote haemodynamic monitoring, cardiac implantable electronic devices (CIEDs), wearables and telehealth interventions. The sex- and race-based disparities are multifactorial: stringent clinical trial inclusion criteria, distrust of the medical establishment, poor access to healthcare, socioeconomic inequities, and lack of diversity in clinical trial leadership. Notwithstanding addressing the above factors, RPM has the unique potential to reduce disparities through a combination of implicit bias mitigation and earlier detection and intervention for HF disease progression in disadvantaged groups. This review describes the uptake of remote haemodynamic monitoring, CIEDs and telehealth in female patients and black patients with HF, and discusses aetiologies that may contribute to inequities and strategies to promote health equity.

1 June 2022 in Journal of Cardiac Failure
Verified
Journal Article
Open access
IMIoannis Mastoris
Ioannis Mastoris
HSHarriette G.C. Van Spall
Harriette G.C. Van Spall
SSSeth H. Sheldon
Seth H. Sheldon
RPRhea C. Pimentel
Rhea C. Pimentel
LSLeslie Steinkamp
Leslie Steinkamp
ASAndrew J. Sauer
Andrew J. Sauer
Cardiac implantable electronic devices, including implantable cardioverter-defibrillators and therapy, are part of guideline-indicated treatment for a subset of patients with heart failure with reduced ejection fraction. Current technological advancements in cardiac implantable electronic devices have allowed the detection of specific physiological parameters that are used to forecast clinical decompensation through algorithmic, multiparameter remote monitoring. Other recent emerging technologies, including cardiac contractility modulation and baroreflex activation therapy, may provide symptomatic or physiological benefits in patients without indications for cardiac resynchronization. Our goal in this state-of-the-art review is to describe the new commercially available technologies, their purported mechanisms of action, and the evidence surrounding their clinical roles, limitations and future directions. Finally, we underline the need for standardized workflow and close interdisciplinary management of this population to ensure the delivery of high-quality care.

14 November 2020 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
ZSZubair Shah
Zubair Shah
IMIoannis Mastoris
Ioannis Mastoris
PAPrakash Acharya
Prakash Acharya
ARAniket S. Rali
Aniket S. Rali
MMMoghni Mohammed
Moghni Mohammed
TATravis Abicht
Travis Abicht
Background: Left ventricular assist devices (LVAD) have been increasingly used in the treatment of end-stage heart failure. While warfarin has been uniformly recommended in the long-term as anticoagulation strategy, no clear recommendation exists for the post-operative period. We sought to evaluate the feasibility of enoxaparin in the immediate and early postoperative period after LVAD implantation. Methods: This is a two-center, retrospective analysis of 250 consecutive patients undergoing LVAD implantation between January 2017 and December 2018. Patients were bridged postoperatively to therapeutic INR by either receiving unfractionated heparin (UFH) or low molecular weight heparin (LMWH). Patients were followed while inpatient and for 3 months after LVAD implantation. The efficacy outcome was occurrence of first and subsequent cerebrovascular accident while safety outcome was the occurrence of bleeding events. Length of stay (LOS) was also assessed. Results: Two hundred fifty and 246 patients were analyzed for index admission and 3-month follow up respectively. No statistically significant differences were found between the two groups in CVA (OR = 0.67; CI = 0.07–6.39, P = 0.73) or bleeding events (OR = 0.91; CI = 0.27–3.04, P = 0.88) during index admission. Similarly, there were no differences at 3 months in either CVAs or bleeding events (OR = 0.85; 0.31–2.34; p = 0.76). No fatal events occurred during the study follow-up period. Median LOS was significantly lower (4 days; p = 0.03) in the LMWH group. Conclusions: LMWH in the immediate and early postoperative period after LVAD implantation appears to be a concurrently safe and efficacious option allowing earlier postoperative discharge and avoidance of recurrent hospitalizations due to sub-therapeutic INR.

31 January 2022 in Indian Heart Journal
Verified
Journal Article
Open access
STSiva S. Taduru
Siva S. Taduru
AGAmandeep Goyal
Amandeep Goyal
TDTarun Dalia
Tarun Dalia
IMIoannis Mastoris
Ioannis Mastoris
ARAniket S. Rali
Aniket S. Rali
ZSZubair Shah
Zubair Shah
Although seen in ∼5% of sarcoidosis patients, cardiac sarcoidosis (CS) accounts for nearly 25% of disease-related deaths. This study aimed to describe characteristics and outcomes among CS patients. Patients diagnosed with CS in 2016–2017 in the US National Inpatient Sample Database were evaluated to study patient characteristics, reasons ascribed to admission, in-hospital outcomes, and complications. A total of 2420 patients (median age 56 years) were included in the analysis. Most admissions occurred due to ventricular tachycardia (12.8%), followed by myocarditis (9.9%) with a mean length of stay of 7 ± 7 days. The overall incidence of in-hospital mortality was 2.5%.